J Korean Soc Menopause.  2013 Aug;19(2):74-80.

Risk Factors Associated with Premalignant and Malignant Endometrial Polyps

• Lee HS
• Cho YJ
• Kim JM

Abstract

OBJECTIVES
The objective of this study is to evaluate the prevalence of endometrial premalignant and malignant polyps in women who underwent hysteroscopic polypectomies, and to investigate whether clinical parameters predict histopathologic outcomes.
METHODS
A review was carried out on the medical records of patients who had undergone hysteroscopic endometrial polypectomy from January 2010 to December 2011. One thousand one hundred ninety-six women who ranged in age from 16 to 81 years were included in the study. Polyps were classified as benign (endometrial polyps and polyps with non-atypical simple hyperplasia and non-atypical complex hyperplasia), premalignant (polyps with atypical simple hyperplasia or atypical complex hyperplasia), or malignant. A statistical analysis was then performed.
RESULTS
Histopathologically, 96.7% benign, 1.1% premalignant, and 2.2% malignant lesions were detected. Abnormal uterine bleeding and postmenopause were the only factors which were determined to be associated with a higher risk of malignancy, with an odds ratios of 5.07 (95% CI, 2.25-11.41) and 3.41 (95% CI, 1.14-10.24), respectively.
CONCLUSION
The risk factors associated with premalignant and malignant endometrial polyps include abnormal uterine bleeding and menopause.

Keyword

Endometrial neoplasm; Hysteroscopy; Menopause; Metrorrhagia; Polyps

MeSH Terms

Endometrial Neoplasms
Female
Humans
Hyperplasia
Hysteroscopy
Medical Records
Menopause
Metrorrhagia
Odds Ratio
Polyps
Postmenopause
Prevalence
Risk Factors
Uterine Hemorrhage

Reference

1. Antunes A Jr, Costa-Paiva L, Arthuso M, Costa JV, Pinto-Neto AM. Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy. Maturitas. 2007; 57:415–421.

2. Peterson WF, Novak ER. Endometrial polyps. Obstet Gynecol. 1956; 8:40–49.

3. Savelli L, De Iaco P, Santini D, Rosati F, Ghi T, Pignotti E, et al. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol. 2003; 188:927–931.

4. Ben-Arie A, Goldchmit C, Laviv Y, Levy R, Caspi B, Huszar M, et al. The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol. 2004; 115:206–210.

5. Shushan A, Revel A, Rojansky N. How often are endometrial polyps malignant? Gynecol Obstet Invest. 2004; 58:212–215.

6. Ferrazzi E, Zupi E, Leone FP, Savelli L, Omodei U, Moscarini M, et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol. 2009; 200:235.e1–235.e6.

7. Machtinger R, Korach J, Padoa A, Fridman E, Zolti M, Segal J, et al. Transvaginal ultrasound and diagnostic hysteroscopy as a predictor of endometrial polyps: risk factors for premalignancy and malignancy. Int J Gynecol Cancer. 2005; 15:325–328.

8. Goldstein SR, Zeltser I, Horan CK, Snyder JR, Schwartz LB. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol. 1997; 177:102–108.

9. Baiocchi G, Manci N, Pazzaglia M, Giannone L, Burnelli L, Giannone E, et al. Malignancy in endometrial polyps: a 12-year experience. Am J Obstet Gynecol. 2009; 201:462.e1–462.e4.

10. Lee SC, Kaunitz AM, Sanchez-Ramos L, Rhatigan RM. The oncogenic potential of endometrial polyps: a systematic review and meta-analysis. Obstet Gynecol. 2010; 116:1197–1205.

11. Wang JH, Zhao J, Lin J. Opportunities and risk factors for premalignant and malignant transformation of endometrial polyps: management strategies. J Minim Invasive Gynecol. 2010; 17:53–58.

12. Gregoriou O, Konidaris S, Vrachnis N, Bakalianou K, Salakos N, Papadias K, et al. Clinical parameters linked with malignancy in endometrial polyps. Climacteric. 2009; 12:454–458.

13. Rahimi S, Marani C, Renzi C, Natale ME, Giovannini P, Zeloni R. Endometrial polyps and the risk of atypical hyperplasia on biopsies of unremarkable endometrium: a study on 694 patients with benign endometrial polyps. Int J Gynecol Pathol. 2009; 28:522–528.

14. Domingues AP, Lopes H, Dias I, De Oliveira CF. Endometrial polyps in postmenopausal women. Acta Obstet Gynecol Scand. 2009; 88:618–620.

15. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989; 160:126–131.

16. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985; 56:403–412.

17. Sivridis E, Giatromanolaki A. Prognostic aspects on endometrial hyperplasia and neoplasia. Virchows Arch. 2001; 439:118–126.

18. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19:41–47.

19. Lee SH, Kim TH, Lee HH, Lee WS, Chung SH. The clinical manifestation of the gynecologic emergency in postmenopausal women. J Korean Soc Menopause. 2012; 18:119–123.

20. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol. 2010; 28:788–792.

21. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006; 106:812–819.

22. Cho YJ, Kim ML, Kim JM, Joo KY, Lee IK. The rate of malignant endometrial polyps and it's associated factors. Korean J Obstet Gynecol. 2007; 50:180–186.

23. Cravello L, de Montgolfier R, D'Ercole C, Boubli L, Blanc B. Hysteroscopic surgery in postmenopausal women. Acta Obstet Gynecol Scand. 1996; 75:563–566.

24. Tjarks M, Van Voorhis BJ. Treatment of endometrial polyps. Obstet Gynecol. 2000; 96:886–889.

25. American Association of Gynecologic Laparoscopists. AAGL practice report: practice guidelines for the diagnosis and management of endometrial polyps. J Minim Invasive Gynecol. 2012; 19:3–10.

26. Wethington SL, Herzog TJ, Burke WM, Sun X, Lerner JP, Lewin SN, et al. Risk and predictors of malignancy in women with endometrial polyps. Ann Surg Oncol. 2011; 18:3819–3823.

27. Costa-Paiva L, Godoy CE Jr, Antunes A Jr, Caseiro JD, Arthuso M, Pinto-Neto AM. Risk of malignancy in endometrial polyps in premenopausal and postmenopausal women according to clinicopathologic characteristics. Menopause. 2011; 18:1278–1282.

28. Fernández-Parra J, Rodríguez Oliver A, López Criado S, Parrilla Fernández F, Montoya Ventoso F. Hysteroscopic evaluation of endometrial polyps. Int J Gynaecol Obstet. 2006; 95:144–148.

29. Speleman F, Dal Cin P, Van Roy N, Van Marck E, Buytaert P, Van den Berghe H, et al. Is t(6;20)(p21;q13) a characteristic chromosome change in endometrial polyps? Genes Chromosomes Cancer. 1991; 3:318–319.

30. Dal Cin P, De Wolf F, Klerckx P, Van Den Berghe H. The 6p21 chromosome region is nonrandomly involved in endometrial polyps. Gynecol Oncol. 1992; 46:393–396.

31. Oguz S, Sargin A, Kelekci S, Aytan H, Tapisiz OL, Mollamahmutoglu L. The role of hormone replacement therapy in endometrial polyp formation. Maturitas. 2005; 50:231–236.

32. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet. 2000; 356:881–887.